Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Oral LBH589 in Refractory Multiple Myeloma
2006-004087-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Overall response rate (CR + PR). Started Jan 2007; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-004087-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004087-31.